News

Data for the recombinant factor VIII (rFVIII) product NovoEight® were presented at the 56th Annual Meeting of the American Society of Hematology (ASH). The post hoc analysis from

In one long-term study of pediatric patients with acute lymphoblastic leukemia (ALL), results showed that 36 of 39 pediatric patients with relapsed/refractory (r/r) ALL, or 92%, experienced complete

Results showed high levels of response in patients with relapsed or refractory classical Hodgkin Lymphoma (HL), with an overall response rate of 87% (n=20) and stable disease in

AML is an aggressive and deadly type of blood cancer, in which the body produces too many of a specific type of white blood cell (myeloblast), which can

The data from the AETHERA trial were featured at the 56th American Society of Hematology (ASH) Annual Meeting press program today and will be presented in an oral

During the trial, 30 patients with stage III-IV melanoma received about four cycles of pIL-12 EP into superficial cutaneous, subcutaneous and nodal lesions on days one, five and

The trial is designed to evaluate CPI-613, in combination with bendamustine and rituximab, in these NHL patients. CPI-613 is a first-in-class anticancer compound designed to disrupt the altered

Sources close to the matter have been cited by The Wall Street Journal as saying that the deal could be announced as early as this week. The acquisition

The application covers composition of matter for KP415, the company’s NME prodrug of methylphenidate. KP415 is designed to be a controlled release (CR), abuse-deterrent methylphenidate product and is